Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026
Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Fineline Cube Jul 20, 2026
Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Fineline Cube Jul 20, 2026
Company Drug

Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia

Fineline Cube Jul 20, 2026
Company Medical Device

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Fineline Cube Feb 28, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...

Company Drug

Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study

Fineline Cube Feb 28, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...

Company Drug

CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT

Fineline Cube Feb 28, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...

Company Drug

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer

Fineline Cube Feb 28, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...

Company Drug

Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval

Fineline Cube Feb 28, 2025

China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...

Company Drug

Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL

Fineline Cube Feb 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...

Company Deals

EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases

Fineline Cube Feb 27, 2025

EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...

Company Drug

AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study

Fineline Cube Feb 27, 2025

UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...

Company Drug

Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study

Fineline Cube Feb 27, 2025

German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...

Company

Ping An Good Doctor Launches AI-Powered Digital Doctor Service

Fineline Cube Feb 27, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...

Company

Eli Lilly to Establish Four New US Pharma Manufacturing Sites

Fineline Cube Feb 27, 2025

US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...

Company Drug

Precigen’s RRP Therapy PRGN-2012 Gets FDA Review

Fineline Cube Feb 27, 2025

US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...

Company Deals

Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine

Fineline Cube Feb 27, 2025

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with...

Company Deals

Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field

Fineline Cube Feb 27, 2025

Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...

Company Drug

InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum

Fineline Cube Feb 27, 2025

Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...

Company Drug

Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia

Fineline Cube Feb 27, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...

Company Drug

Hepalink Pharmaceutical’s Enoparin Receives Argentina Approval for Thromboembolic Diseases

Fineline Cube Feb 27, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) announced that its subsidiary, Shenzhen Techdow...

Company Medical Device

Bio-heart’s Iberis System Approved by NMPA for Hypertension Treatment

Fineline Cube Feb 27, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) announced that its subsidiary, Shanghai Angiocare...

Company Drug

Fosun Pharma’s Tenapanor Approved in China for CKD Dialysis Patients

Fineline Cube Feb 27, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received...

Company Deals

WuXi XDC Expands MOU with LigaChem to Advance Next-Gen ADC Development

Fineline Cube Feb 26, 2025

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Posts pagination

1 … 236 237 238 … 697

Recent updates

  • Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms
  • China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure
  • CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years
  • Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China
  • Easton Pharmaceutical Secures NMPA Approval for China’s First Generic Remimazolam Besylate, Challenging Humanwell’s Ruima Monopoly in Procedural Sedation and General Anesthesia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Fujian Province Launches Comprehensive Biomedical Innovation Support Framework with Accelerated Listing, Premium Pricing, and Enhanced Insurance Coverage Mechanisms

Policy / Regulatory

China’s NMPA Suspends Medochemie’s Tramadol Hydrochloride Capsules Following Non-Compliant Overseas Inspection and Documentation Failure

Company Drug

CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China’s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months–17 Years

Company Deals

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.